Sage Journals: Discover world-class research

Abstract

Background:

Baseline brain volume (BV) is predictive at a group level but is difficult to interpret at the single patient level.

Objective:

To validate BV cutoffs able to identify clinically relevant atrophy in relapsing–remitting multiple sclerosis (RRMS) patients.

Methods:

The expected normalized brain volume (NBV) for each patient was calculated using RRMS patients from two phase III clinical trials, applying a linear formula developed on the baseline variable of an independent data set. The difference between these expected NBV values and those actually observed was calculated and used to categorize the patients in the low-NBV, medium-NBV, and high-NBV groups.

Results:

The 2-year probability of 3-month confirmed disability worsening was significantly associated with the NBV categorization (p = 0.006), after adjusting for treatment effect. Taking the high-NBV group as a reference, the hazard ratios for the medium-NBV and low-NBV groups were 1.22 (95% confidence interval (CI): 0.85–1.76, p = 0.27) and 1.69 (95% CI: 1.11–2.57, p = 0.01), respectively.

Conclusion:

This study validates the use of BV cutoffs to identify clinically relevant atrophy in RRMS study by showing that the three groups classified according to the baseline NBV adjusted for the other prognostic variables have a significant prognostic impact on the risk of disability progression.

Keywords

Multiple sclerosis normalized brain volume disability progression laquinimod

Get full access to this article

View all access options for this article.

References

De Stefano

Airas

Grigoriadis

et al . Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014; 28: 147–156.

De Stefano

Stromillo

Giorgio

et al . Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015; 87: 93–99.

Sormani

De Stefano

Francis

et al . Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler 2015; 21: 916–924.

Kappos

De Stefano

Freedman

et al . Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 2016; 22(10): 1297–1305.

Popescu

Agosta

Hulst

et al . Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 1082–1091.

Jacobsen

Hagemeier

Myhr

et al . Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014; 85: 1109–1115.

Radue

Barkhof

Kappos

et al . Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 2015; 84: 784–793.

Tauhid

Chu

Sasane

et al . Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol 2015; 262: 2425–2432.

Mowry

Beheshtian

Waubant

et al . Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72: 1760–1765.

10.

Kappos

Radue

O’Connor

et al . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

11.

Calabresi

Radue

Goodin

et al . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545–556.

12.

Sormani

Kappos

Radue

et al . Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult Scler 2017; 23(5): 656–664.

13.

Vollmer

Sorensen

Selmaj

et al . A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 2014; 261(4): 773–783.

14.

Comi

Jeffery

Kappos

et al . Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366(11): 1000–1009.

15.

International Conference on Harmonisation (ICH). ICH harmonized tripartite guideline. Guideline for good clinical practice (current step 4 version dated 10 June 1996). In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf

16.

World Medical Association. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects, https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (2013, accessed 27 April 2017).

17.

Smith

Zhang

Jenkinson

et al . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material